JDRF's Research Frontline e-mail newsletter is published approximately every 6 to 8 weeks to provide the latest information about research on Type 1 diabetes and its complications.
Subscribe by sending an e-mail to communications@jdrf.ca. Please include "Subscribe Research Frontline" in the subject line.
Read the current issues:
- Targeting the B cell prevents diabetes in mice
- Successful encapsulation of beta cell precursors
- Why beta cell regeneration slows with age
- With the switch of a gene, non-insulin producing cells make insulin
- Connecting people with diabetes to clinical trials
- Two drugs for hypertension may address diabetic retinopathy
- In development: A novel oral vaccine for type 1 diabetes autoimmunity
- JDRFI, GNF form innovative partnership
- Researchers gather to discuss the complications of diabetes and obesity
- JDRFI Partner Bayhill Enters Collaboration with Genentech to Develop Type 1 Vaccine
- Progress on the stem cell front
- A gene in mice may hold clues to treatments for people
- In the near future, a clinical trial of regulatory T cells
- Progress in the field of islet transplantation
- Cancer drugs reverse type 1 diabetes in mice
- A potential new approach for treating diabetic eye disease
- Stem cell policy repealed
- A promising new therapy
- Metabolic abnormalities precede autoimmunity in type 1 children
- Scientists find a way to encourage the replication of adult human beta cells
- An important new field of study: the epigenetics of type 1 diabetes
- A new gastrin combination therapy reverses diabetes in mice
- Type 1 diabetes and celiac disease are genetically linked
- A link between diabetes prevention and the hygiene hypothesis
- The protein interferon-alpha appears to trigger type 1 diabetes
- Transplanted islets survive in mice without the use of immunosuppressive drugs
- Towards evaluating pancreatic beta cells in vivo
- Using dendritic cells to control autoimmunity
- Scientific presentations focus on adults with Type 1 diabetes
- Success in growing human beta cells in vitro
- An antibody therapy activates key regulatory cells, alters disease progression
- Human stem cells, when translplanted into mice, are fully functional
- An “Inflammatory Signature” In Both New-Onset and At-Risk Patients
- Genetics Protects Some Individuals From Diabetic Kidney Disease
- At Last, The Elusive Pancreatic Progenitor Cell
Read previous issues:
- Tumor-Suppressing Protein Regulates Beta Cell Growth
- Human Skin Cells Reprogrammed to Embryonic State
- JDRF Industry Partners in Drug Development Alliances with Major Pharma Companies
- Fatty Acid in Diet May Lower Type 1 Diabetes Risk
- Current Transplant Drugs May Hinder Beta Cell Regeneration
- Discovery of Fourth Diabetes Antibody Should Aid Prediction
- Taking Antibody Orally May Help Block Diabetes
- Stopping Islet Inflammation May Be Key for Type 1 Prevention
- Gene Provides Clues To Development of Type 1
- "Diabulimia": young girls with Type 1 diabetes skipping insulin doses to lose weight
- Mouse Skin Cells Reprogrammed to Embryonic State
- Powerful Research Method Finds Four New Type 1 Diabetes Genetic Regions
- Clinical Trial of Diabetes Regenerative Therapy Shows Positive Results
- Glucagon May Add Another Dimension To Artificial Pancreas
- Immune System Pathway May Be Key Route for Preventing Diabetes
- Scientific Paper Retracted
- Natural Compounds Prevent Diabetes By Blocking Immune Cell Channel
- Amniotic Fluid-Derived Stem Cells Show Potential
- Drug Shown to Protect Against Diabetic Retinopathy
- Agreement to Develop Complications Drugs Results From 16 Years of Research
- Bone Marrow Cells From Humans Repair Islet Cells in Mice
- Novocell Creates Insulin-Secreting Cells From Embryonic Stem Cells
- Researchers Clarify Initial Stage of Autoimmune Attack
